Top

International Journal of Diabetes in Developing Countries

Published in:

01-10-2018 | Original Article

Replication of MACF1 gene variant rs2296172 with type 2 diabetes susceptibility in the Bania population group of Punjab, India

Authors: Varun Sharma, Itty Sethi, Indu Sharma, Gurvinder Singh, Ankit Mahajan, Arshia Angural, A. J. S. Bhanwer, Manoj K. Dhar, K. K. Pandita, Vinod Singh, Ekta Rai, Swarkar Sharma

Published in: International Journal of Diabetes in Developing Countries | Issue 4/2018

Abstract

Microtubule actin cross-linking factor 1 (MACF1) gene variant rs2296172 has recently been associated with type 2 diabetes (T2D). However, this variant has never been evaluated as such in Indian populations. In the present replication study, we genotyped variant rs2296172 by Taqman allele discrimination assay in 432 individuals belonging to the Bania caste group from Punjab, India. The single-nucleotide polymorphism (SNP) was evaluated for association with T2D, in a population based candidate gene case-control association study design, by estimating odds ratio with 95% confidence interval. The SNP rs2296172 of MACF1 was found to be significantly associated with T2D (p = 0.02) and odds ratio (OR) = 1.59 (1.06–2.38) at 95% CI . We further emphasize that the Indian population as such is a conglomeration of various endogamous population groups. It is critical that such replication studies be carried out in various populations to find association of variants to T2D susceptibility and understand genetic heterogeneity. However, it is important to avoid pooling of samples to address the concern of population stratification.

Available only for authorised users

Forouhi NG, Wareham NJ. Epidemiology of diabetes. Med (Abingdon, England : UK Ed). 2014;42(12):698–702. https://doi.org/10.1016/j.mpmed.2014.09.007.CrossRef

Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes: worthless or valuable? Diabetes Care. 2013;36(Suppl 2):S120–6. https://doi.org/10.2337/dcS13-2009.CrossRefPubMedPubMedCentral

Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes. 2015;6(1):87–123. https://doi.org/10.3390/genes6010087.CrossRefPubMedPubMedCentral

Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9):981–90. https://doi.org/10.1038/ng.2383.CrossRefPubMedPubMedCentral

Moorjani P, Thangaraj K, Patterson N, Lipson M, Loh P-R, Govindaraj P, et al. Genetic evidence for recent population mixture in India. Am J Hum Genet. 2013;93(3):422–38. https://doi.org/10.1016/j.ajhg.2013.07.006.CrossRefPubMedPubMedCentral

Sharma V, Sharma I, Sethi I, Mahajan A, Singh G, Angural A, et al. Replication of newly identified type 2 diabetes susceptible loci in Northwest Indian population. Diabetes Res Clin Pract. 2017;126:160–3. https://doi.org/10.1016/j.diabres.2017.02.013.CrossRefPubMed

Albrechtsen A, Grarup N, Li Y, Sparso T, Tian G, Cao H, et al. Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. Diabetologia. 2013;56(2):298–310. https://doi.org/10.1007/s00125-012-2756-1.CrossRefPubMed

Leung CL, Sun D, Zheng M, Knowles DR, Liem RK. Microtubule actin cross-linking factor (MACF): a hybrid of dystonin and dystrophin that can interact with the actin and microtubule cytoskeletons. J Cell Biol. 1999;147(6):1275–86. https://doi.org/10.1083/jcb.147.6.1275.CrossRefPubMedPubMedCentral

Jørgensen LH, Mosbech M-B, Færgeman NJ, Graakjaer J, Jacobsen SV, Schrøder HD. Duplication in the microtubule-actin cross-linking factor 1 gene causes a novel neuromuscular condition. Sci Rep. 2014;4(1):5180. https://doi.org/10.1038/srep05180. http://www.nature.com/articles/srep05180#supplementary-information.CrossRefPubMedPubMedCentral

10.

Hu L, Su P, Li R, Yin C, Zhang Y, Shang P, et al. Isoforms, structures, and functions of versatile spectraplakin MACF1. BMB Rep. 2016;49(1):37–44. https://doi.org/10.5483/BMBRep.2016.49.1.185.CrossRefPubMedPubMedCentral

11.

Kodama A, Karakesisoglou I, Wong E, Vaezi A, Fuchs E. ACF7: an essential integrator of microtubule dynamics. Cell. 2003;115(3):343–54.

12.

Gong TW, Besirli CG, Lomax MI. MACF1 gene structure: a hybrid of plectin and dystrophin. Mamm Genome. 2001;12(11):852–61. https://doi.org/10.1007/s00335-001-3037-3.CrossRefPubMed

13.

Kodama A, Karakesisoglou I, Wong E, Vaezi A, Fuchs E. ACF7: an essential integrator of microtubule dynamics. Cell. 2003;115(3):343–54. https://doi.org/10.1016/S0092-8674(03)00813-4.CrossRefPubMed

14.

Wu X, Kodama A, Fuchs E. ACF7 regulates cytoskeletal-focal adhesion dynamics and migration and has ATPase activity. Cell. 2008;135(1):137–48. https://doi.org/10.1016/j.cell.2008.07.045.CrossRefPubMedPubMedCentral

15.

Jijakli H, Zhang HX, Dura E, Ramirez R, Sener A, Malaisse WJ. Effects of cytochalasin B and D upon insulin release and pancreatic islet cell metabolism. Int J Mol Med. 2002;9(2):165–72.PubMed

16.

Thurmond DC, Gonelle-Gispert C, Furukawa M, Halban PA, Pessin JE. Glucose-stimulated insulin secretion is coupled to the interaction of actin with the t-SNARE (target membrane soluble N-ethylmaleimide-sensitive factor attachment protein receptor protein) complex. Mol Endocrinol. 2003;17(4):732–42. https://doi.org/10.1210/me.2002-0333.CrossRefPubMed

17.

Sharma V, Sharma I, Singh VP, Verma S, Pandita A, Singh V, et al. mtDNA G10398A variation provides risk to type 2 diabetes in population group from the Jammu region of India. Meta Gene. 2014;2:269–73. https://doi.org/10.1016/j.mgene.2014.02.003.CrossRefPubMedPubMedCentral

18.

WD DWaP. PS power and sample size program available for free on the internet. Controlled Clin Trials. 1997;18:274.CrossRef

19.

Karakesisoglou I, Yang Y, Fuchs E. An epidermal plakin that integrates actin and microtubule networks at cellular junctions. J Cell Biol. 2000;149(1):195–208. https://doi.org/10.1083/jcb.149.1.195.CrossRefPubMedPubMedCentral

20.

Orci L, Gabbay KH, Malaisse WJ. Pancreatic beta-cell web: its possible role in insulin secretion. Science. 1972;175(4026):1128–30. https://doi.org/10.1126/science.175.4026.1128.CrossRefPubMed

21.

Tomas A, Yermen B, Min L, Pessin JE, Halban PA. Regulation of pancreatic beta-cell insulin secretion by actin cytoskeleton remodelling: role of gelsolin and cooperation with the MAPK signalling pathway. J Cell Sci. 2006;119(Pt 10):2156–67. https://doi.org/10.1242/jcs.02942.CrossRefPubMed

22.

Ka M, Jung EM, Mueller U, Kim WY. MACF1 regulates the migration of pyramidal neurons via microtubule dynamics and GSK-3 signaling. Dev Biol. 2014;395(1):4–18. https://doi.org/10.1016/j.ydbio.2014.09.009.CrossRefPubMedPubMedCentral

23.

Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets. 2006;7(11):1435–41. https://doi.org/10.2174/1389450110607011435.CrossRefPubMed

Title: Replication of MACF1 gene variant rs2296172 with type 2 diabetes susceptibility in the Bania population group of Punjab, India
Authors: Varun Sharma
Itty Sethi
Indu Sharma
Gurvinder Singh
Ankit Mahajan
Arshia Angural
A. J. S. Bhanwer
Manoj K. Dhar
K. K. Pandita
Vinod Singh
Ekta Rai
Swarkar Sharma
Publication date: 01-10-2018
Publisher: Springer India
Published in: International Journal of Diabetes in Developing Countries / Issue 4/2018
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-017-0598-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Prevalence of type 2 diabetes mellitus in Southern Cross River: a cross-sectional observational survey

Sleep and diabetes and the kidney

Screening for diabetic retinopathy by non-mydriatic fundus camera in a Turkish population

Glycosylated hemoglobin-defined prediabetes and cardiovascular risk markers in rural India: the Nallampatti noncommunicable disease study

Association of HSD11B1 rs12086634 and HSD11B1 rs846910 gene polymorphisms with polycystic ovary syndrome in South Indian women

Statins protect diabetic myocardial microvascular endothelial cells from injury

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials